The Many Faces of the A2b Adenosine Receptor in Cardiovascular and Metabolic Diseases

Journal of Cellular Physiology

Volumn 230, Issue 12, 2015, Pages 2891-2897

  Eisenstein, Anna ^a   Patterson, Shenia ^a   Ravid, Katya ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2B RECEPTOR; C REACTIVE PROTEIN; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR ANTAGONIST; CARDIOVASCULAR AGENT;

ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CORONARY ARTERY OCCLUSION; CORONARY REPERFUSION; HEMATOPOIETIC CELL; INTESTINE EPITHELIUM CELL; ISCHEMIC PRECONDITIONING; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE; METABOLIC DISORDER; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PERFUSION PRESSURE; PRIORITY JOURNAL; PULMONARY ARTERY SMOOTH MUSCLE CELL; REVIEW; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; CARDIOVASCULAR DISEASES; DRUG EFFECTS; HUMAN; METABOLIC DISEASES; METABOLISM; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION;

ADENOSINE A2 RECEPTOR AGONISTS; ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HUMANS; METABOLIC DISEASES; MOLECULAR TARGETED THERAPY; RECEPTOR, ADENOSINE A2B; SIGNAL TRANSDUCTION;

EID: 84937581070     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.25043     Document Type: Review

References (95)

1. Anvari F, Sharma AK, Fernandez LG, Hranjec T, Ravid K, Kron IL, Laubach VE. 2010. Tissue-derived proinflammatory effect of adenosine A2B receptor in lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg 140:871-877.
2. Balwierczak JL, Sharif R, Krulan CM, Field FP, Weiss GB, Miller MJ. 1991. Comparative effects of a selective adenosine A2 receptor agonist, CGS 21680, I and nitroprusside in vascular smooth muscle. Eur J Pharmacol 196:117-123.
3. Bodin P, Burnstock G. 1998. Increased release of ATP from endothelial cells during acute inflammation. Inflamm Res 47:351-354.
4. Bodin P, Burnstock G. 2001. Purinergic signalling: ATP release. Neurochem Res 26:959-969.
5. Bot I, de Vries H, Korporaal SJ, Foks AC, Bot M, van Veldhoven J, Ter Borg MN, van Santbrink PJ, van Berkel TJ, Kuiper J, Ijzerman AP. 2012. Adenosine A(2)B receptor agonism inhibits neointimal lesion development after arterial injury in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 32:2197-2205.
6. Burnstock G 2002. Purinergic signaling and vascular cell proliferation and death. Arterioscler Thromb Vasc Biol 22:364-373.
7. Chunn JL, Molina JG, Mi T, Xia Y, Kellems RE, Blackburn MR. 2005. Adenosine-dependent pulmonary fibrosis in adenosine deaminase-deficient mice. J Immunol 175:1937-1946.
8. Csoka B, Koscso B, Toro G, Kokai E, Virag L, Nemeth ZH, Pacher P, Bai P, Hasko G. 2014. A2B adenosine receptors prevent insulin resistance by inhibiting adipose tissue inflammation via maintaining alternative macrophage activation. Diabetes 63:850-866.
9. Csoka B, Nemeth ZH, Rosenberger P, Eltzschig HK, Spolarics Z, Pacher P, Selmeczy Z, Koscso B, Himer L, Vizi ES, Blackburn MR, Deitch EA, Hasko G. 2010. A2B adenosine receptors protect against sepsis-induced mortality by dampening excessive inflammation. J Immunol 185:542-550.
10. Csoka B, Selmeczy Z, Koscso B, Nemeth ZH, Pacher P, Murray PJ, Kepka-Lenhart D, Morris SM, Jr., Gause WC, Leibovich SJ, Hasko G. 2012. Adenosine promotes alternative macrophage activation via A2A and A2B receptors. FASEB J 26:376-386.
11. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. 2010. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol 56:1897-1907.
12. Dixon AK, Gubitz AK, Sirinathsinghji DJ, Richardson PJ, Freeman TC. 1996. Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol 118:1461-1468.
13. Douglas JS, Jr., Holmes DR, Jr., Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, Morris DC, Liberman H, Parker K, Jurkovitz C, Murrah N, Foster J, Hyde P, Mancini GB, Weintraub WS. 2005. Coronary stent restenosis in patients treated with cilostazol. Circulation 112:2826-2832.
14. Drury AN, Szent-Gyorgyi A. 1929. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J Physiol 68:213-237.
15. Dubey RK, Gillespie DG, Jackson EK. 1999. Adenosine inhibits collagen and total protein synthesis in vascular smooth muscle cells. Hypertension 33:190-194.
16. Dubey RK, Gillespie DG, Mi Z, Jackson EK. 1998. Adenosine inhibits growth of human aortic smooth muscle cells via A2B receptors. Hypertension 31:516-521.
17. Dubey RK, Gillespie DG, Shue H, Jackson EK. 2000. A(2B) receptors mediate antimitogenesis in vascular smooth muscle cells. Hypertension 35:267-272.
18. Eckle T, Faigle M, Grenz A, Laucher S, Thompson LF, Eltzschig HK. 2008a. A2B adenosine receptor dampens hypoxia-induced vascular leak. Blood 111:2024-2035.
19. Eckle T, Grenz A, Laucher S, Eltzschig HK. 2008b. A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice. J Clin Invest 118:3301-3315.
20. Eckle T, Hartmann K, Bonney S, Reithel S, Mittelbronn M, Walker LA, Lowes BD, Han J, Borchers CH, Buttrick PM, Kominsky DJ, Colgan SP, Eltzschig HK. 2012. Adora2b-elicited Per2 stabilization promotes a HIF-dependent metabolic switch crucial for myocardial adaptation to ischemia. Nat Med 18:774-782.
21. Eckle T, Kohler D, Lehmann R, El Kasmi K, Eltzschig HK. 2008. Hypoxia-inducible factor-1 is central to cardioprotection: A new paradigm for ischemic preconditioning. Circulation 118:166-175.
22. Eckle T, Krahn T, Grenz A, Kohler D, Mittelbronn M, Ledent C, Jacobson MA, Osswald H, Thompson LF, Unertl K, Eltzschig HK. 2007. Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. Circulation 115:1581-1590.
23. Eisenstein A, Carroll SH, Johnston-Cox H, Farb M, Gokce N, Ravid K. 2014. An adenosine receptor-Kruppel-like factor 4 protein axis inhibits adipogenesis. J Biol Chem 289:21071-21081.
24. El-Tayeb A, Michael S, Abdelrahman A, Behrenswerth A, Gollos S, Nieber K, Muller CE. 2011. Development of polar adenosine A2A receptor agonists for inflammatory bowel disease: Synergism with A2B antagonists. ACS Med Chem Lett 2:890-895.
25. Eltzschig HK, Carmeliet P. 2011. Hypoxia and inflammation. N Engl J Med 364:656-665.
26. Eltzschig HK, Ibla JC, Furuta GT, Leonard MO, Jacobson KA, Enjyoji K, Robson SC, Colgan SP. 2003. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: Role of ectonucleotidases and adenosine A2B receptors. J Exp Med 198:783-796.
27. Elzein E, Kalla RV, Li X, Perry T, Gimbel A, Zeng D, Lustig D, Leung K, Zablocki J. 2008. Discovery of a novel A2B adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseases. J Med Chem 51:2267-2278.
28. Field JJ, Nathan DG, Linden J. 2014. The role of adenosine signaling in sickle cell therapeutics. Hematol Oncol Clin North Am 28:287-299.
29. Figler RA, Wang G, Srinivasan S, Jung DY, Zhang Z, Pankow JS, Ravid K, Fredholm B, Hedrick CC, Rich SS, Kim JK, LaNoue KF, Linden J. 2011. Links between insulin resistance, adenosine A2B receptors, and inflammatory markers in mice and humans. Diabetes 60:669-679.
30. Fredholm BB 2007. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 14:1315-1323.
31. Fredholm BBAPIJ, Jacobson KA, Linden J, Muller CE. 2011. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol Rev 63:1-34.
32. Fredholm BB, Irenius E, Kull B, Schulte G. 2001. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem Pharmacol 61:443-448.
33. Gessi S, Fogli E, Sacchetto V, Merighi S, Varani K, Preti D, Leung E, Maclennan S, Borea PA. 2010. Adenosine modulates HIF-1{alpha}, VEGF, IL-8, and foam cell formation in a human model of hypoxic foam cells. Arterioscler Thromb Vasc Biol 30:90-97.
34. Gessi S, Merighi S, Varani K, Borea PA. 2011. Adenosine receptors in health and disease. Adv Pharmacol 61:41-75.
35. Glass CK, Witztum JL. 2001. Atherosclerosis. the road ahead. Cell 104:503-516.
36. Hansson GK, Hermansson A. 2011. The immune system in atherosclerosis. Nat Immunol 12:204-212.
37. Harada H, Asano O, Hoshino Y, Yoshikawa S, Matsukura M, Kabasawa Y, Niijima J, Kotake Y, Watanabe N, Kawata T, Inoue T, Horizoe T, Yasuda N, Minami H, Nagata K, Murakami M, Nagaoka J, Kobayashi S, Tanaka I, Abe S. 2001. 2-Alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: Their synthesis and structure-activity relationships toward hepatic glucose production induced via agonism of the A(2B) receptor. J Med Chem 44:170-179.
38. Hasko G, Linden J, Cronstein B, Pacher P. 2008. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 7:759-770.
39. Haynes J, Jr., Obiako B, Thompson WJ, Downey J. 1995. Adenosine-induced vasodilation: Receptor characterization in pulmonary circulation. Am J Physiol 268:H1862-H1868.
40. Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, Kent KM, Griffin J, Leon MB. 1996. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 94:1247-1254.
41. Hotamisligil GS 2006. Inflammation and metabolic disorders. Nature 444:860-867.
42. Hua X, Kovarova M, Chason KD, Nguyen M, Koller BH, Tilley SL. 2007. Enhanced mast cell activation in mice deficient in the A2b adenosine receptor. J Exp Med 204:117-128.
43. Jackson EK, Ren J, Gillespie DG. 2011. 2′, 3′-cAMP, 3′-AMP, and 2′-AMP inhibit human aortic and coronary vascular smooth muscle cell proliferation via A2B receptors. Am J Physiol Heart Circ Physiol 301:H391-H401.
44. Jiang G, Li T, Qiu Y, Rui Y, Chen W, Lou Y. 2007. RNA interference for HIF-1alpha inhibits foam cells formation in vitro. Eur J Pharmacol 562:183-190.
45. Johansson SM, Salehi A, Sandstrom ME, Westerblad H, Lundquist I, Carlsson PO, Fredholm BB, Katz A. 2007. A1 receptor deficiency causes increased insulin and glucagon secretion in mice. Biochem Pharmacol 74:1628-1635.
46. Johnston-Cox H, Eisenstein AS, Koupenova M, Carroll S, Ravid K. 2014. The macrophage A2B adenosine receptor regulates tissue insulin sensitivity. PLoS One 9:e88775.
47. Johnston-Cox H, Koupenova M, Yang D, Corkey B, Gokce N, Farb MG, LeBrasseur N, Ravid K. 2012. The A2b adenosine receptor modulates glucose homeostasis and obesity. PLoS One 7:e40584.
48. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J. 2010. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis. Lancet 375:132-140.
49. Karmouty-Quintana H, Zhong H, Acero L, Weng T, Melicoff E, West JD, Hemnes A, Grenz A, Eltzschig HK, Blackwell TS, Xia Y, Johnston RA, Zeng D, Belardinelli L, Blackburn MR. 2012. The A2B adenosine receptor modulates pulmonary hypertension associated with interstitial lung disease. FASEB J 26:2546-2557.
50. Kearney M, Pieczek A, Haley L, Losordo DW, Andres V, Schainfeld R, Rosenfield K, Isner JM. 1997. Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation 95:1998-2002.
51. Koeppen M, Harter PN, Bonney S, Bonney M, Reithel S, Zachskorn C, Mittelbronn M, Eckle T. 2012. Adora2b signaling on bone marrow derived cells dampens myocardial ischemia-reperfusion injury. Anesthesiology 116:1245-1257.
52. Kolachala V, Asamoah V, Wang L, Obertone TS, Ziegler TR, Merlin D, Sitaraman SV. 2005. TNF-alpha upregulates adenosine 2b (A2b) receptor expression and signaling in intestinal epithelial cells: A basis for A2bR overexpression in colitis. Cell Mol Life Sci 62:2647-2657.
53. Kolachala V, Ruble B, Vijay-Kumar M, Wang L, Mwangi S, Figler H, Figler R, Srinivasan S, Gewirtz A, Linden J, Merlin D, Sitaraman S. 2008. Blockade of adenosine A2B receptors ameliorates murine colitis. Br J Pharmacol 155:127-137.
54. Komatsu R, Ueda M, Naruko T, Kojima A, Becker AE. 1998. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation 98:224-233.
55. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. 1998. In-stent restenosis: Contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 31:224-230.
56. Koupenova M, Johnston-Cox H, Vezeridis A, Gavras H, Yang D, Zannis V, Ravid K. 2012. A2b adenosine receptor regulates hyperlipidemia and atherosclerosis. Circulation 125:354-363.
57. Kreckler LM, Wan TC, Ge ZD, Auchampach JA. 2006. Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. J Pharmacol Exp Ther 317:172-180.
58. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Kang SJ, Park SJ, Lee JH, Choi SW, Seong IW, Lee NH, Cho YH, Shin WY, Lee SJ, Hyon MS, Bang DW, Choi YJ, Kim HS, Lee BK, Lee K, Park HK, Park CB, Lee SG, Kim MK, Park KH, Park WJ. 2011. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: Results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial. J Am Coll Cardiol 57:1264-1270.
59. Libby P, Ridker PM, Hansson GK. 2011. Progress and challenges in translating the biology of atherosclerosis. Nature 473:317-325.
60. Linden J 2005. Adenosine in tissue protection and tissue regeneration. Mol Pharmacol 67:1385-1387.
61. Lusis AJ 2000. Atherosclerosis. Nature 407:233-241.
62. Maas JE, Wan TC, Figler RA, Gross GJ, Auchampach JA. 2010. Evidence that the acute phase of ischemic preconditioning does not require signaling by the A 2B adenosine receptor. J Mol Cell Cardiol 49:886-893.
63. Martin PL, Potts AA. 1994. The endothelium of the rat renal artery plays an obligatory role in A2 adenosine receptor-mediated relaxation induced by 5′-N-ethylcarboxamidoadenosine and N6-cyclopentyladenosine. J Pharmacol Exp Ther 270:893-899.
64. Moore KJ, Tabas I. 2011. Macrophages in the pathogenesis of atherosclerosis. Cell 145:341-355.
65. Murphy SL, Xu J, Kochanek KD. 2013. Deaths: Final data for 2010. Natl Vital Stat Rep 61:1-117.
66. Murry CE, Jennings RB, Reimer KA. 1986. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 74:1124-1136.
67. Mustafa SJ, Nadeem A, Fan M, Zhong H, Belardinelli L, Zeng D. 2007. Effect of a specific and selective A(2B) adenosine receptor antagonist on adenosine agonist AMP and allergen-induced airway responsiveness and cellular influx in a mouse model of asthma. J Pharmacol Exp Ther 320:1246-1251.
68. Nemeth ZH, Bleich D, Csoka B, Pacher P, Mabley JG, Himer L, Vizi ES, Deitch EA, Szabo C, Cronstein BN, Hasko G. 2007. Adenosine receptor activation ameliorates type 1 diabetes. FASEB J 21:2379-2388.
69. Nemeth ZH, Lutz CS, Csoka B, Deitch EA, Leibovich SJ, Gause WC, Tone M, Pacher P, Vizi ES, Hasko G. 2005. Adenosine augments IL-10 production by macrophages through an A2B receptor-mediated posttranscriptional mechanism. J Immunol 175:8260-8270.
70. Nguyen DK, Montesinos MC, Williams AJ, Kelly M, Cronstein BN. 2003. Th1 cytokines regulate adenosine receptors and their downstream signaling elements in human microvascular endothelial cells. J Immunol 171:3991-3998.
71. Pedroza M, Schneider DJ, Karmouty-Quintana H, Coote J, Shaw S, Corrigan R, Molina JG, Alcorn JL, Galas D, Gelinas R, Blackburn MR. 2011. Interleukin-6 contributes to inflammation and remodeling in a model of adenosine mediated lung injury. PLoS One 6:e22667.
72. Roiron C, Sanchez P, Bouzamondo A, Lechat P, Montalescot G. 2006. Drug eluting stents: An updated meta-analysis of randomised controlled trials. Heart 92:641-649.
73. Rubino A, Ralevic V, Burnstock G. 1995. Contribution of P1-(A2b subtype) and P2-purinoceptors to the control of vascular tone in the rat isolated mesenteric arterial bed. Br J Pharmacol 115:648-652.
74. Rusing D, Muller CE, Verspohl EJ. 2006. The impact of adenosine and A(2B) receptors on glucose homoeostasis. J Pharm Pharmacol 58:1639-1645.
75. Ryzhov S, Zaynagetdinov R, Goldstein AE, Novitskiy SV, Blackburn MR, Biaggioni I, Feoktistov I. 2008. Effect of A2B adenosine receptor gene ablation on adenosine-dependent regulation of proinflammatory cytokines. J Pharmacol Exp Ther 324:694-700.
76. Sitaraman SV, Merlin D, Wang L, Wong M, Gewirtz AT, Si-Tahar M, Madara JL. 2001. Neutrophil-epithelial crosstalk at the intestinal lumenal surface mediated by reciprocal secretion of adenosine and IL-6. J Clin Invest 107:861-869.
77. Sluimer JC, Gasc JM, van Wanroij JL, Kisters N, Groeneweg M, Sollewijn Gelpke MD, Cleutjens JP, van den Akker LH, Corvol P, Wouters BG, Daemen MJ, Bijnens AP. 2008. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am Coll Cardiol 51:1258-1265.
78. St Hilaire C, Koupenova M, Carroll SH, Smith BD, Ravid K. 2008. TNF-alpha upregulates the A2B adenosine receptor gene: The role of NAD(P)H oxidase 4. Biochem Biophys Res Commun 375:292-296.
79. Sun CX, Zhong H, Mohsenin A, Morschl E, Chunn JL, Molina JG, Belardinelli L, Zeng D, Blackburn MR. 2006. Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J Clin Invest 116:2173-2182.
80. Sun Y, Duan Y, Eisenstein AS, Hu W, Quintana A, Lam WK, Wang Y, Wu Z, Ravid K, Huang P. 2012. A novel mechanism of control of NFkappaB activation and inflammation involving A2B adenosine receptors. J Cell Sci 125:4507-4517.
81. van der Hoeven D, Wan TC, Gizewski ET, Kreckler LM, Maas JE, Van Orman J, Ravid K, Auchampach JA. 2011. A role for the low-affinity A2B adenosine receptor in regulating superoxide generation by murine neutrophils. J Pharmacol Exp Ther 338:1004-1012.
82. Weber C, Noels H. 2011. Atherosclerosis: Current pathogenesis and therapeutic options. Nat Med 17:1410-1422.
83. Wellen KE, Hotamisligil GS. 2005. Inflammation, stress, and diabetes. J Clin Invest 115:1111-1119.
84. Woollard KJ, Geissmann F. 2010. Monocytes in atherosclerosis: Subsets and functions. Nat Rev Cardiol 7:77-86.
85. Wynne BM, Chiao CW, Webb RC. 2009. Vascular smooth muscle cell signaling mechanisms for contraction to angiotensin II and endothelin-1. J Am Soc Hypertens 3:84-95.
86. Xi J, McIntosh R, Shen X, Lee S, Chanoit G, Criswell H, Zvara DA, Xu Z. 2009. Adenosine A2A and A2B receptors work in concert to induce a strong protection against reperfusion injury in rat hearts. J Mol Cell Cardiol 47:684-690.
87. Yang D, Koupenova M, McCrann DJ, Kopeikina KJ, Kagan HM, Schreiber BM, Ravid K. 2008. The A2b adenosine receptor protects against vascular injury. Proc Natl Acad Sci U S A 105:792-796.
88. Yang D, Zhang Y, Nguyen HG, Koupenova M, Chauhan AK, Makitalo M, Jones MR, St Hilaire C, Seldin DC, Toselli P, Lamperti E, Schreiber BM, Gavras H, Wagner DD, Ravid K. 2006. The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. J Clin Invest 116:1913-1923.
89. Yasuda N, Inoue T, Horizoe T, Nagata K, Minami H, Kawata T, Hoshino Y, Harada H, Yoshikawa S, Asano O, Nagaoka J, Murakami M, Abe S, Kobayashi S, Tanaka I. 2003. Functional characterization of the adenosine receptor contributing to glycogenolysis and gluconeogenesis in rat hepatocytes. Eur J Pharmacol 459:159-166.
90. Zaynagetdinov R, Ryzhov S, Goldstein AE, Yin H, Novitskiy SV, Goleniewska K, Polosukhin VV, Newcomb DC, Mitchell D, Morschl E, Zhou Y, Blackburn MR, Peebles RS, Jr., Biaggioni I, Feoktistov I. 2010. Attenuation of chronic pulmonary inflammation in A2B adenosine receptor knockout mice. Am J Respir Cell Mol Biol 42:564-571.
91. Zernecke A, Weber C. 2010. Chemokines in the vascular inflammatory response of atherosclerosis. Cardiovasc Res 86:192-201.
92. Zhang W, Zhang Y, Wang W, Dai Y, Ning C, Luo R, Sun K, Glover L, Grenz A, Sun H, Tao L, Colgan SP, Blackburn MR, Eltzschig HK, Kellems RE, Xia Y. 2013. Elevated ecto-5′-nucleotidase-mediated increased renal adenosine signaling via A2B adenosine receptor contributes to chronic hypertension. Circ Res 112:1466-1478.
93. Zhong H, Belardinelli L, Maa T, Feoktistov I, Biaggioni I, Zeng D. 2004. A(2B) adenosine receptors increase cytokine release by bronchial smooth muscle cells. Am J Respir Cell Mol Biol 30:118-125.
94. Zhong H, Belardinelli L, Maa T, Zeng D. 2005. Synergy between A2B adenosine receptors and hypoxia in activating human lung fibroblasts. Am J Respir Cell Mol Biol 32:2-8.
95. Zhou Y, Mohsenin A, Morschl E, Young HW, Molina JG, Ma W, Sun CX, Martinez-Valdez H, Blackburn MR. 2009. Enhanced airway inflammation and remodeling in adenosine deaminase-deficient mice lacking the A2B adenosine receptor. J Immunol 182:8037-8046.